Hypertriglyceridemia and cardiovascular risk reduction
References (97)
- et al.
Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study
Am J Cardiol
(1992) Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
Am J Cardiol
(1998)- et al.
Obesity and dyslipidemia
Endocrinol Metab Clin North Am
(2003) Niacin as a component of combination therapy for dyslipidemia
- et al.
Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
J Lipid Res.
(1981) - et al.
Effectiveness of oncenightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
Am J Cardiol.
(1998) - et al.
Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism ofaction of niacin
Metabolism.
(1985) - et al.
Efficacy and safety of an extended-release niacin (niaspan): A long-term study
Am J Cardiol.
(1998) - et al.
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: An 8-week, randomized, double-blind, placebo-controlled study
Clin Ther
(2005) - et al.
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Am J Cardiol.
(2005)
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
Am J Cardiol.
(1998)
Comparison of statins in hypertriglyceridemia
Am J Cardiol.
(1998)
Omacor in familial combined hyperlipidemia: Effects on lipids and low density lipoprotein subclasses
Atherosclerosis
(2000)
Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
J Am Coll Cardiol.
(1986)
Secondary prevention of macro vascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial
Lancet
(2005)
Prediction of coronary heart disease using risk factor categories
Circulation
(1998)
Plasma triglyceride level is a risk factor for cardiovascular disease independent of highdensity lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
J Cardiouasc Risk
(1996)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
Circulation
(2002)
Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program AdultTreatment Panel
JAMA
(1993)
Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey
JAMA
(2002)
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
Diabetes
(2003)
The emergence of triglycerides as a significant independent risk factor in coronary artery disease
Eur Heart J.
(1998)
Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
Circulation
(1998)
The complex role of triglycerides in cardiovascular disease
Semin Vasc Med.
(2002)
Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
Am J Cardiol
(1999)
Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceriderich lipoproteins to their unique human monocyte-macrophage receptor
Arterioscler Thromb Vasc Biol.
(1998)
Change in LDL particle size is associated with change in plasma tri glyceride concentration
Arterioscler Thromb.
(1992)
Elevated remnant like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study
Diabetes Care
(2002)
Atherogenic lipoprotein phenotype. A proposed genetic mark er for coronary heart disease risk
Circulation
(1990)
Low-density lipoprotein subclass patterns and risk of myo cardial infarction
JAMA
(1988)
The metabolic syndrome as predictor of type 2 diabetes: The San Antonio Heart Study
Diabet Care
(2003)
The metabolic syndrome and total and cardiovascular dis ease mortality in middle-aged men
JAMA
(2002)
Dyslipidemia management in adults with diabetes
Diabetes Care
(2004)
Demystifying triglycerides: A practical approach for the clinician
Cleve Clin J Med
(2005)
Cardiovascular morbidity and mortality associated with the metabolic syndrome
Diabetes Care
(2001)
Prevalence and trends in obesity among US adults, 1999–2000
JAMA
(2002)
Unraveling the complex genetics of familial combined hyperlipidemia
Ann Med.
(2006)
Familial lipoprotein disorders in patients with premature coronary artery disease
Circulation
(1992)
Management of primary hyperlipidemia
N Engl J Med.
(1995)
Diabetes, plasma insulin, and cardiovascular disease: Subgroup analy sis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
Arch Intern Med.
(2002)
Cardiovascular risk beyond LDL-C levels. Other lipids are performers in cholesterol story
Postgrad Med.
(2004)
The insulin resistance syndrome: Definition and dietary approaches to treatment
Annu Rev Nutr.
(2005)
Accumulated evidence on fish consumption and coronary heart disease mortality: A meta-analysis of cohort studies
Circulation
(2004)
Why triglycerides need to be aggressively managed: A guide for physicians
Cardiovasc Rev Rep
(2003)
Mechanism of action of fibrates on lipid and lipoprotein metabolism
Circulation
(1998)
Niacin decreases removal of highdensity lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport
Arterioscler Thromb Vasc Biol
(1997)
Cited by (117)
Relationship between lifestyle habits and cardiovascular risk factors in familial hypercholesterolemia
2023, Nutrition, Metabolism and Cardiovascular DiseasesBioactive Compounds of Winery by-products: Extraction Techniques and their Potential Health Benefits
2022, Applied Food ResearchCitation Excerpt :Hyperlipidemia is a term that refers to elevated levels of triglycerides or cholesterol in the blood. Micro and macro vascular complications such as cerebrovascular, microangiopathy, cardiovascular and other metabolic disorders are consequences of long term hyperlipidemia (Jacobson et al., 2007). Various studies were conducted to demonstrate the role of grape seed extract in controlling postprandial hyperlipidemia.
Chromatographic fractions from Chrysophyllum albidum stem bark boost antioxidant enzyme activity and ameliorate some markers of diabetes complications
2021, Journal of Traditional and Complementary MedicineDevelopment and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity
2019, Journal of Drug Delivery Science and Technology
Copyright © 2007 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.